[Form 4] SUTRO BIOPHARMA, INC. Insider Trading Activity
Sutro Biopharma (STRO) reported an insider purchase on Form 4. CFO Gregory K. Chow bought 19,750 shares of common stock on 10/15/2025 with transaction code P (purchase). The weighted average price was $0.81, with individual trades executed between $0.8099 and $0.8100. Following the transaction, he beneficially owned 19,750 shares, held directly.
Sutro Biopharma (STRO) ha riportato un'acquisto da insider tramite Form 4. Il CFO Gregory K. Chow ha acquistato 19.750 azioni di azioni ordinarie il 15/10/2025 con il codice di transazione P (acquisto). Il prezzo medio ponderato è stato di 0,81 USD, con operazioni singole eseguite tra 0,8099 USD e 0,8100 USD. A seguito della transazione, deteneva 19.750 azioni, possedute direttamente.
Sutro Biopharma (STRO) informó de una compra de insider en el Formulario 4. El CFO Gregory K. Chow compró 19.750 acciones de acciones ordinarias el 15/10/2025 con código de transacción P (compra). El precio medio ponderado fue de $0.81, con operaciones individuales ejecutadas entre $0.8099 y $0.8100. Después de la transacción, poseía de forma beneficiosa 19.750 acciones, poseídas directamente.
Sutro Biopharma (STRO)가 Form 4에서 내부자 매수를 보고했습니다. CFO Gregory K. Chow가 19,750주의 보통주를 P 거래코드로 매수했습니다. 2025-10-15일에 매수했습니다. 가중 평균가는 $0.81였고 개별 거래는 $0.8099와 $0.8100 사이에 실행되었습니다. 거래 후 그는 19,750주를 직접 보유한 수익자(beneficial owner)로 남아 있습니다.
Sutro Biopharma (STRO) a signalé un achat d'initié sur le formulaire 4. Le directeur financier Gregory K. Chow a acheté 19 750 actions ordinaires le 15/10/2025 avec le code de transaction P (achat). Le prix moyen pondéré était de 0,81 USD, les transactions individuelles ayant été exécutées entre 0,8099 USD et 0,8100 USD. Suite à la transaction, il possédait 19 750 actions, en propriété bénéficiaire et détenues directement.
Sutro Biopharma (STRO) meldete einen Insider-Kauf auf Formular 4. CFO Gregory K. Chow kaufte am 15.10.2025 19.750 Aktien Stammaktien mit dem Transaktionscode P (Kauf). Der gewichtete Durchschnittspreis betrug 0,81 USD, wobei einzelne Trades zwischen 0,8099 USD und 0,8100 USD durchgeführt wurden. Nach der Transaktion besaß er 19.750 Aktien in wirtschaftlichem Eigentum, direkt gehalten.
Sutro Biopharma (STRO) أبلغت عن شراء من الداخل على النموذج 4. اشترى المدير المالي Gregory K. Chow 19,750 سهماً من الأسهم العادية في 15/10/2025 مع رمز المعاملة P (شراء). كان السعر المتوسط المرجّح $0.81، مع تنفيذ صفقات فردية بين $0.8099 و $0.8100. عقب الصفقة، كان يمتلك 19,750 سهماً، مباشرةً.
Sutro Biopharma (STRO) 在表格4上报告内部人士交易。CFO Gregory K. Chow 于 2025-10-15 购买了 19,750 股普通股,交易代码为 P(买入)。加权平均价格为 $0.81,单笔交易价格在 $0.8099 至 $0.8100 之间。交易完成后,他以受益所有人身份直接持有 19,750 股。
- None.
- None.
Sutro Biopharma (STRO) ha riportato un'acquisto da insider tramite Form 4. Il CFO Gregory K. Chow ha acquistato 19.750 azioni di azioni ordinarie il 15/10/2025 con il codice di transazione P (acquisto). Il prezzo medio ponderato è stato di 0,81 USD, con operazioni singole eseguite tra 0,8099 USD e 0,8100 USD. A seguito della transazione, deteneva 19.750 azioni, possedute direttamente.
Sutro Biopharma (STRO) informó de una compra de insider en el Formulario 4. El CFO Gregory K. Chow compró 19.750 acciones de acciones ordinarias el 15/10/2025 con código de transacción P (compra). El precio medio ponderado fue de $0.81, con operaciones individuales ejecutadas entre $0.8099 y $0.8100. Después de la transacción, poseía de forma beneficiosa 19.750 acciones, poseídas directamente.
Sutro Biopharma (STRO)가 Form 4에서 내부자 매수를 보고했습니다. CFO Gregory K. Chow가 19,750주의 보통주를 P 거래코드로 매수했습니다. 2025-10-15일에 매수했습니다. 가중 평균가는 $0.81였고 개별 거래는 $0.8099와 $0.8100 사이에 실행되었습니다. 거래 후 그는 19,750주를 직접 보유한 수익자(beneficial owner)로 남아 있습니다.
Sutro Biopharma (STRO) a signalé un achat d'initié sur le formulaire 4. Le directeur financier Gregory K. Chow a acheté 19 750 actions ordinaires le 15/10/2025 avec le code de transaction P (achat). Le prix moyen pondéré était de 0,81 USD, les transactions individuelles ayant été exécutées entre 0,8099 USD et 0,8100 USD. Suite à la transaction, il possédait 19 750 actions, en propriété bénéficiaire et détenues directement.
Sutro Biopharma (STRO) meldete einen Insider-Kauf auf Formular 4. CFO Gregory K. Chow kaufte am 15.10.2025 19.750 Aktien Stammaktien mit dem Transaktionscode P (Kauf). Der gewichtete Durchschnittspreis betrug 0,81 USD, wobei einzelne Trades zwischen 0,8099 USD und 0,8100 USD durchgeführt wurden. Nach der Transaktion besaß er 19.750 Aktien in wirtschaftlichem Eigentum, direkt gehalten.
FAQ
What insider transaction did STRO report?
A Form 4 reporting that CFO Gregory K. Chow purchased 19,750 common shares on 10/15/2025.
How many STRO shares were bought and at what price?
19,750 shares at a weighted average price of $0.81, with trades between $0.8099 and $0.8100.
What is the transaction code for the STRO insider trade?
Code P, which indicates a purchase.
How many STRO shares does the insider own after the trade?
19,750 shares beneficially owned directly following the reported transaction.
Who is the reporting person in this STRO Form 4?
Gregory K. Chow, Chief Financial Officer.
On what date did the STRO insider transaction occur?
10/15/2025.
Does the filing provide price detail for each trade?
It provides a weighted average and a $0.8099–$0.8100 range, with a note offering full breakdown upon request.